Stock Research for OPHT

OPHT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

OPHT Stock Chart & Research Data

The OPHT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OPHT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


OPHT Due diligence Resources & Stock Charts

The OPHT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View OPHT Detailed Price Forecast - CNN Money CNN View OPHT Detailed Summary - Google Finance
Yahoo View OPHT Detailed Summary - Yahoo! Finance Zacks View OPHT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View OPHT Trends & Analysis - Trade-Ideas Barrons View OPHT Major Holders - Barrons
NASDAQ View OPHT Call Transcripts - NASDAQ Seeking View OPHT Breaking News & Analysis - Seeking Alpha
Spotlight View OPHT Annual Report - CompanySpotlight.com OTC Report View OPHT OTC Short Report - OTCShortReport.com
TradeKing View OPHT Fundamentals - TradeKing Charts View OPHT SEC Filings - Bar Chart
WSJ View Historical Prices for OPHT - The WSJ Morningstar View Performance/Total Return for OPHT - Morningstar
MarketWatch View the Analyst Estimates for OPHT - MarketWatch CNBC View the Earnings History for OPHT - CNBC
StockMarketWatch View the OPHT Earnings - StockMarketWatch MacroAxis View OPHT Buy or Sell Recommendations - MacroAxis
Bullish View the OPHT Bullish Patterns - American Bulls Short Pains View OPHT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View OPHT Stock Mentions - StockTwits PennyStocks View OPHT Stock Mentions - PennyStockTweets
Twitter View OPHT Stock Mentions - Twitter Invest Hub View OPHT Investment Forum News - Investor Hub
Yahoo View OPHT Stock Mentions - Yahoo! Message Board Seeking Alpha View OPHT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for OPHT - SECform4.com Insider Cow View Insider Transactions for OPHT - Insider Cow
CNBC View OPHT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for OPHT - OTC Markets
Yahoo View Insider Transactions for OPHT - Yahoo! Finance NASDAQ View Institutional Holdings for OPHT - NASDAQ


Stock Charts

FinViz View OPHT Stock Insight & Charts - FinViz.com StockCharts View OPHT Investment Charts - StockCharts.com
BarChart View OPHT Stock Overview & Charts - BarChart Trading View View OPHT User Generated Charts - Trading View




Latest Financial News for OPHT


Is Ophthotech Corporation (NASDAQ:OPHT) Attractive At Its Current PE Ratio?
Posted on Wednesday September 12, 2018

This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...


Why Is Ophthotech (OPHT) Up 5.8% Since Last Earnings Report?
Posted on Friday August 31, 2018

Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.


Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published in Proceedings of the National Academy of Sciences
Posted on Wednesday August 22, 2018

Ophthotech Corporation (OPHT) announced today that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on an adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) licensed by Ophthotech. In June 2018, Ophthotech announced that it entered into an exclusive global license agreement with the University of Florida Research Foundation and Penn for rights to develop and commercialize this novel AAV gene therapy product candidate for the treatment of RHO-adRP.


Edited Transcript of OPHT earnings conference call or presentation 1-Aug-18 12:00pm GMT
Posted on Friday August 17, 2018

Q2 2018 Ophthotech Corp Earnings Call


Stock Market & Investing Books

Enter a stock symbol to view the stock details.